医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Samsung Bioepis Settles Patent Disputes with AbbVie, Clearing the Way for the Commercialization of SB5 (Adalimumab) in All Approved Markets Worldwide

2018年04月05日 PM09:05
このエントリーをはてなブックマークに追加


 

INCHEON, Korea

Samsung Bioepis Co., Ltd. today announced that it has signed a licensing agreement with AbbVie Inc., settling all pending patent litigation between the two companies and clearing the way for the worldwide commercialization of Samsung Bioepis’ SB5, a biosimilar referencing Humira® i (adalimumab), in all approved markets worldwide. Under the terms of the agreement, SB5 may be launched in Europe from October 16, 2018 onwards and, if approved, in the United States (US) from June 30, 2023 onwards.

SB5 has been granted marketing authorization by the European Commission (EC) as IMRALDI®, and will be commercialized in Europe by Biogen. In the US, SB5 has not yet received regulatory approval.

“We welcome this agreement which clears the way for SB5 in approved markets across the world. The earliest impact of this agreement will likely be seen in Europe, where SB5 has already been approved and is expected to become our third TNF inhibitor available in the region,” said Jaywoo Kim, Senior Vice President and Head of the Commercial Division at Samsung Bioepis. “Through relentless process innovation and an uncompromising commitment to quality, we remain dedicated to advancing one of the industry’s strongest biosimilar pipelines, so that more patients and healthcare systems across the world may benefit from biosimilars.”

About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that includes six late-stage candidates that cover the therapeutic areas of immunology, oncology and diabetes. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

i Humira® is a registered trademark of AbbVie Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180405005492/en/

CONTACT

MEDIA CONTACT:
Samsung Bioepis Co., Ltd.
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Exactech Earns Research Award at International Computer-Assisted Surgery Conference for ExactechGPS® Knee Application
  • 火山噴火で家屋の破壊と住民の避難が続く中、ハワイ・コミュニティ財団が支援基金を創設
  • Octapharma宣布Nuwiq®产品新增剂量规格在欧洲获准,提高了血友病A患者的给药灵活性
  • PHCホールディングス株式会社:薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始
  • LG化学举办“全球创新大赛 (GIC)”“寻找改变世界的创新技术”